The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 283, Issue 4 46-4, 2002, Pages

  Rolin, Bidda ^a   Larsen, Marianne O ^a   Gotfredsen, Carsten F ^a   Deacon, Carolyn F ^b   Carr, Richard D ^a   Wilken, Michael ^a   Knudsen, Lotte Bjerre ^a  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Animal models; Diabetes; Glucagon like peptide 1; Incretin hormones

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; LIRAGLUTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CELL VOLUME; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HISTOLOGY; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

EID: 0036784675     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00030.2002     Document Type: Article

References (41)

1. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
2. The GLP-1 derivative NN2211 inhibits cytokine-induced apoptosis in primary rat β-cells
3. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo
4. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in anesthetized pig
5. Initiation of increased pancreatic islet growth in young normoglycaemic mice (Umeå +/?)
6. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
7. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute postprandial and 24-h secretion patterns
8. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: A potential role for regulation of specific Bcl family genes toward an apoptotic cell death program
9. GLP-1 promotes satiety and suppresses energy intake in humans
10. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity
11. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on BG concentrations
12. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus
13. Activation of GLP-1 receptor signaling is coupled to inhibition of apoptosis in heterologous cell types
14. Pharmacokinetic profile of the long-acting GLP-1 derivative NN2211 in healthy male subjects
15. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes
16. The glucagon-like peptides
17. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
18. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats
19. β-cell glucotoxicity in the Psammomys obesus model of type 2 diabetes
20. Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
21. Insulinotropic action of GLP-1(7-37) in diabetic and nondiabetic subjects
22. Normalization of fasting hyperglycemia by exogenous GLP-1(7-36)amide in type 2 diabetic patients
23. Glucagon-like peptide-1, a new hormone of the entero-insular axis
24. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach
25. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I
26. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day
27. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats
28. Near normalization of diurnal glucose concentrations by continuous administration of GLP-1 in subjects with NIDDM
29. The role of the gut in regulating food intake in man
30. NN2211, a protracted GLP-1 derivative, ameliorates glycaemia and reduces triglyceride levels in prediabetic ZDF rats
31. Fatty acid-induced β-cell apoptosis: A link between obesity and diabetes
32. The long-acting GLP-1 derivative NN2211 markedly slows the development of diabetes in the male Zucker diabetic fatty rat
33. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats
34. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
35. Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age
36. Glucagonlike peptide I (7-37) actions on endocrine pancreas
37. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
38. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow
39. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats
40. Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)
41. Effect of 6-wk course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity and β-cell function in type 2 diabetes: A parallel group study